Back to Search
MATTHEW MILLWARD, PHARMD
PHARMD
Pharmacist
NPI: 1992087639Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
S018714(AZ)
Research & Publications (20)
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
PMID 19546819·J Thorac Oncol·2009
8-other
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
PMID 19276257·Clin Cancer Res·2009
3-trial
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
PMID 19140204·Cancer·2009
3-trial
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.
PMID 18676140·Eur J Cancer·2008
3-trial
Long-term survival following chemoradiation for inoperable non-small cell lung cancer.
PMID 19012553·Med J Aust·2008
3-trial
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
PMID 17891338·Invest New Drugs·2008
3-trial
Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
PMID 18454162·Br J Cancer·2008
8-other
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
PMID 17488140·Pharmacoeconomics·2007
8-other
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
PMID 17704250·J Nucl Med·2007
8-other
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.
PMID 17235506·Int J Colorectal Dis·2007
4-observational
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
PMID 17453375·Acta Oncol·2007
3-trial
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
PMID 17021960·Invest New Drugs·2007
3-trial
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
PMID 16966688·J Clin Oncol·2006
2-rct
Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.
PMID 16765562·Eur J Surg Oncol·2006
8-other
Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma.
PMID 16417233·J Invest Dermatol·2006
8-other
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
PMID 16969355·Br J Cancer·2006
3-trial
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
PMID 16670205·Ann Oncol·2006
3-trial
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
PMID 16787687·Lung Cancer·2006
2-rct
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.
PMID 15868382·Invest New Drugs·2005
3-trial
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
PMID 15923057·Lung Cancer·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1935 N POWER RD
MESA, AZ 85205 - Phone
- (480) 985-3658
Quick Facts
- NPI
- 1992087639
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile